← Mechanisms of action
PMP22
SINGLE PROTEINHomo sapiens
Preferred name: Peripheral myelin protein 22 ChEMBL ↗
Linked proteins
Drugs acting on this target (14)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| basiliximab (Simulect) | Adcc | approved | mAb | CD25 |
| in 111-dota-basiliximab | Binding agent | experimental | mAb | CD25 |
| adct-301 | Immunity, passive | experimental | mAb | PMP22 immunity, passive |
| anti-tac(fv)-pe38 | Inhibitor | experimental | mAb | PMP22 inhibitor |
| camidanlumab tesirine | Inhibitor | experimental | mAb | PMP22 inhibitor |
| daclizumab (Zenapax) | Inhibitor | approved | mAb | PMP22 inhibitor |
| imtox-25 | Inhibitor | experimental | mAb | PMP22 inhibitor |
| inolimomab | Inhibitor | experimental | mAb | PMP22 inhibitor |
| pxt3003 | Inhibitor | experimental | Small molecule | PMP22 inhibitor |
| ro7296682 | Inhibitor | experimental | mAb | PMP22 inhibitor |
| y90 basiliximab | Inhibitor | experimental | mAb | PMP22 inhibitor |
| y90 humanized anti-tac | Inhibitor | experimental | mAb | PMP22 inhibitor |
| 111in-daclizumab | Radiodepletion | experimental | mAb | PMP22 radiodepletion |
| 90y-daclizumab | Radiodepletion | experimental | mAb | PMP22 radiodepletion |